Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed/Cisplatin followed by Gefitinib vs Gefitinib in East Asian NSCLC
NCT01017874Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Nov 2009; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01017874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01017874.